Showing posts with label outcome. Show all posts
Showing posts with label outcome. Show all posts

Tuesday, September 24, 2013

0 Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

Thorax 67:754-756 doi:10.1136/thoraxjnl-2012-201869


  • Chest clinic



  • Audit update



Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry


This article has been UnlockedFree via Creative Commons: OPEN ACCESS










  1. on behalf of the British Thoracic Society Difficult Asthma Network


+Author Affiliations




  1. 1Centre for Infection and Immunity, Queen’s University of Belfast, Belfast, UK




  2. 2Institute for Lung Health, Department of Infection, Inflammation and Immunity, University of Leicester, Leicester, UK




  3. 3Royal Brompton and Harefield NHS Foundation Trust, London, UK




  4. 4The University of Manchester (MAHSC) and University Hospital of South Manchester, UK




  5. 5Centre for Public Health, Queen’s University of Belfast, Belfast, UK





  1. Correspondence toProfessor Liam G Heaney, Centre for Infection and Immunity, Queen’s University of Belfast, Level 8, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK; l.heaney@qub.ac.uk




  1. Contributors LGH is the coordinator of the British Thoracic Society Difficult Asthma Registry and with JS collated and managed the data for this manuscript. CEB and AM-G and RN co-lead the British Thoracic Society Difficult Asthma Network and all have contributed equally to this manuscript.





  • Received 6 March 2012


  • Accepted 30 March 2012


  • Published Online First 11 May 2012




Abstract


Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.

Full Text







Monday, September 16, 2013

0 Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials

Open AccessResearch

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials



Harold R Collard, Eric Yow, Luca Richeldi, Kevin J Anstrom and Craig Glazer










For all author emails, please log on.








Respiratory Research 2013, 14:73 doi:10.1186/1465-9921-14-73

Published: 13 July 2013





Abstract (provisional)


Background


Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.

Methods


Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.

Results


Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.

Conclusions


In this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.